Tempest Therapeutics Inc
TPST
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.79M
Close$
$-0.10
108.2% downside
Current Fair Value
108.2% downsideOvervalued by 108.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.79 Million |
|---|---|
| Enterprise Value | $12.84 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.33 |
| Beta | -1.69 |
| Outstanding Shares | 10,931,593 |
Return
| Return on Equity | -5243.07% |
|---|---|
| Return on Assets | -400.99% |
| Return on Invested Capital | -583.17% |
Valuation & Multiples
| P/E Ratio | -0.39 |
|---|---|
| PEG | -0.25 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.3 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.61 |
| Debt to Equity | 9.55 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.30
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 12.46%▼ 6.52% |
|---|---|
| Total Invested | $848,109▼ 62.48% |
| Investors Holding | 200% |
ESG Score
No data
About Tempest Therapeutics Inc
13 employees
CEO: Julia Owens Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and t...